By Sara Stefanini ( May 1, 2008, 12:00 AM EDT) -- Despite its recent failure to challenge "pay for delay" settlements between generic-drug makers and brand-name-drug makers in court, the U.S. Federal Trade Commission has indicated its intent to continue to fight such deals, most recently pursuing a widely watched monopolization claim against Cephalon Inc. that could lead to a battle in the U.S. Supreme Court and push Congress to take action....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.